IVI receives $15.7 million to conduct Ph III trials of typhoid vaccine – IVI

News and stories
Careers
Events
Contact us
한국어

Who We Are
What We Do
- Overview
- Discover
- Develop
- Deliver
- Build Capacity
- Disease Areas
  - Cholera
  - Typhoid
  - Dengue
  - MERS
  - Schistosomiasis
  - Chikungunya
  - COVID-19
  - AMR
    - RADAAR
  - Other
- Where We Work
Our Impact

IVI receives $15.7 million to conduct Ph III trials of typhoid vaccine

Home
News IVI in the Media
IVI receives $15.7 million to conduct Ph III trials of typhoid vaccine

IVI receives $15.7 million to conduct Ph III trials of typhoid vaccine

https://www.outsourcing-pharma.com/Article/2019/04/23/IVI-receives-15.7m-to-conduct-Ph-III-trials-of-typhoid-vaccine?

Outsourcing-pharma.com, 2019/04/23

Related posts

06/05/2021

Nature | Six months of COVID vaccines: what 1.7 billion doses have taught scientists

News and stories
Press Releases
Announcements
IVI in the Media
Blog
Newsletters

Subscribe to usemail addressSubscribe

Social Media

Stay Connected

Vision & Mission
Why Vaccines
IVI in Brief
History
Director General’s Message
Policies
- Gender equality
- Environmental Sustainability
State Parties/Signatories

Leadership
Senior Management
Our Partners

Overview
Discover
Develop
Deliver
Build Capacity

Disease Areas
- Cholera
- Typhoid
- Dengue
- MERS
- Schistosomiasis
- Chikungunya
- COVID-19
- Other

Journal Publications
International Vaccinology Course
News and stories
Annual Reports & Financial Statement

Korea Support Committee for IVI (KSC)

Copyright 2021 International Vaccine Institute. All Rights Reserved.

No translations available for this page

News and stories
Careers
Events
Contact us
한국어